Browse the full management transaction log of Pediatrix Medical Group, Inc., a listed equity based in United States. Shares trade on US US, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Pediatrix Medical Group, Inc. has logged 4 insider filings. Market capitalisation: €1.8bn. The latest transaction was reported on 14 May 2026 (Cession). Among the most active insiders: Weis Shirley A. The full history is accessible without an account.
4 of 4 declarations
Pediatrix Medical Group, Inc. is a U.S.-listed healthcare services company trading on the NYSE under ticker MD. The company is based in Sunrise, Florida, in the United States. Its operating history dates back to 1979, and over time it built a national reputation as a physician-led specialist focused on women, newborns and children. In 2022, the company formally renamed itself from Mednax to Pediatrix Medical Group, a brand consolidation intended to create a clearer identity across its affiliated practices and improve recognition among hospitals, clinicians and patients. From a business perspective, Pediatrix is now centered on high-acuity medical services, with core capabilities in neonatology, maternal-fetal medicine and other pediatric subspecialties. The group works through specialized physician teams and contractual arrangements with hospitals and other healthcare facilities, allowing it to deliver both clinical expertise and operational support. Its value proposition is closely tied to quality of care, hospital partnership, cost containment and risk mitigation. The company historically maintained a broad network of affiliated practices across the country. However, its portfolio has been deliberately reshaped in recent periods. According to its 2025 annual report, Pediatrix exited almost all of its affiliated office-based practices in 2024, except for maternal-fetal medicine, and also exited its primary and urgent care service line. This is an important strategic signal: management has been narrowing the business toward more specialized and differentiated service lines rather than trying to operate a broader primary-care platform. In competitive terms, Pediatrix positions itself as a trusted hospital solutions partner with strong clinical depth in maternity, neonatal and pediatric care. Its competitive edge lies in specialty expertise, embedded relationships with hospitals, and the ability to support care quality while helping clients manage staffing, operations and clinical outcomes. The company also emphasizes advanced clinical tools, quality initiatives, training and data-driven processes to support performance. Geographically, Pediatrix is primarily a United States healthcare platform, operating through a nationwide network of physician practices and hospital-based programs. Recent highlights include the 2022 name change, the 2024 portfolio reset, and continued public-facing messaging in 2025 and 2026 around its hospital solutions and pediatric specialty care platform. For investors, Pediatrix is best viewed as a U.S. specialty healthcare operator focused on clinical specialization, operational discipline and a more streamlined business mix, with the NYSE listing adding visibility for international equity market participants.